Chronic hepatitis C and liver fibrosis

10.1111/j.1478-3231.2008.01934.x

10.1017/S0950268805005340

10.1016/j.cgh.2010.08.026

10.1016/j.jhep.2007.04.006

10.1186/1471-2458-9-34

Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, Jewett A, Baack B, Rein DB, Patel N. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012;61:1-32.

10.1002/hep.23220

Alberti A, Chemello L, Benvegnù L. Natural history of hepatitis C. J Hepatol 1999;31 Suppl 1:17-24.

Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998;28:930-938.

Ikeda K. CotPaCoVH. Hepatitis and liver cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C Washington: Institute of Medicine of the Natioinal Academies; 2010;.

10.1093/cid/cis011

10.1515/CCLM.2011.001

10.1172/JCI24282

10.1038/nrgastro.2010.97

10.1016/j.bpg.2011.02.005

10.1007/978-3-642-27340-7_2

10.1007/978-3-642-27340-7_3

Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005;436:933-938.

10.1002/hep.510230202

10.1002/jmv.1095

10.1016/S0002-9440(10)63964-8

10.1038/sj.cdd.4401121

Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004;126:529-540.

10.1074/jbc.M113.492314

10.1074/jbc.M410161200

10.1073/pnas.171311298

10.1074/jbc.M100698200

10.1053/jhep.2002.32968

10.1016/j.ejim.2012.05.001

Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, Szabo G. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 2004;127:1513-1524.

Schulze-Krebs A, Preimel D, Popov Y, Bartenschlager R, Lohmann V, Pinzani M, Schuppan D. Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology 2005;129:246-258.

10.1053/j.gastro.2010.03.008

Jiao J, Friedman SL, Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol 2009;25:223-229.

Failli P, Ruocco C, De Franco R, Caligiuri A, Gentilini A, Giotti A, Gentilini P, Pinzani M. The mitogenic effect of platelet-derived growth factor in human hepatic stellate cells requires calcium influx. Am J Physiol 1995;269:C1133-C1139.

10.1172/JCI117497

Meyer DH, Bachem MG, Gressner AM. Modulation of hepatic lipocyte proteoglycan synthesis and proliferation by Kupffer cell-derived transforming growth factors type beta 1 and type alpha. Biochem Biophys Res Commun 1990;171:1122-1129.

Svegliati-Baroni G, Ridolfi F, Hannivoort R, Saccomanno S, Homan M, De Minicis S, Jansen PL, Candelaresi C, Benedetti A, Moshage H. Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor. Gastroenterology 2005;128:1042-1055.

Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, Wu Y, Yanase K, Namisaki T, Yamazaki M. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003;52:1347-1354.

10.1136/gut.2005.088690

10.1096/fj.03-1273rev

Rachfal AW, Brigstock DR. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol Res 2003;26:1-9.

10.1002/hep.23046

10.1053/j.gastro.2009.04.011

10.1007/s11010-009-0027-3

10.1038/nrgastro.2010.168

10.1152/ajpgi.00215.2003

10.1002/hep.25545

10.1002/hep.23435

10.1136/gut.2007.120303

10.1016/j.cmet.2007.12.007

10.2353/ajpath.2006.050767

10.1038/labinvest.2010.48

10.1038/labinvest.2010.123

Pinzani M, Abboud HE, Gesualdo L, Abboud SL. Regulation of macrophage colony-stimulating factor in liver fat-storing cells by peptide growth factors. Am J Physiol 1992;262:C876-C881.

Tiggelman AM, Boers W, Linthorst C, Brand HS, Sala M, Chamuleau RA. Interleukin-6 production by human liver (myo)fibroblasts in culture. Evidence for a regulatory role of LPS, IL-1 beta and TNF alpha. J Hepatol 1995;23:295-306.

Czaja MJ, Geerts A, Xu J, Schmiedeberg P, Ju Y. Monocyte chemoattractant protein 1 (MCP-1) expression occurs in toxic rat liver injury and human liver disease. J Leukoc Biol 1994;55:120-126.

Knittel T, Dinter C, Kobold D, Neubauer K, Mehde M, Eichhorst S, Ramadori G. Expression and regulation of cell adhesion molecules by hepatic stellate cells (HSC) of rat liver: involvement of HSC in recruitment of inflammatory cells during hepatic tissue repair. Am J Pathol 1999;154:153-167.

Hellerbrand SC, Tsukamoto H, Brenner DA, Rippe RA. Expression of intracellular adhesion molecule 1 by activated hepatic stellate cells. Hepatology 1996;24:670-676.

10.1055/s-2007-991511

10.1055/s-0030-1255354

Knolle PA, Gerken G. Local control of the immune response in the liver. Immunol Rev 2000;174:21-34.

10.1002/hep.26429

10.1136/gut.2010.211136

10.1152/ajpgi.00522.2005

10.1002/hep.21093

MacDonald GA, Bridle KR, Ward PJ, Walker NI, Houglum K, George DK, Smith JL, Powell LW, Crawford DH, Ramm GA. Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3. J Gastroenterol Hepatol 2001;16:599-606.

10.1002/hep.21867

10.1016/j.jhep.2008.05.014

10.1016/j.jhep.2009.06.027

10.1053/j.gastro.2007.10.011

Fillebeen C, Rivas-Estilla AM, Bisaillon M, Ponka P, Muckenthaler M, Hentze MW, Koromilas AE, Pantopoulos K. Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C Virus. J Biol Chem 2005;280:9049-9057.

10.1016/j.jhep.2010.04.044

10.1053/j.gastro.2011.01.053

10.1002/hep.24787

10.1111/j.1365-2893.2009.01244.x

Pantopoulos K. Function of the hemochromatosis protein HFE: Lessons from animal models. World J Gastroenterol 2008;14:6893-6901.

Pietrangelo A. Hemochromatosis gene modifies course of hepatitis C viral infection. Gastroenterology 2003;124:1509-1523.

10.1053/j.gastro.2008.03.003

10.1111/j.1365-2893.2011.01518.x

10.1002/hep.510230607

10.1016/j.jhep.2013.11.003

Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003;39:239-244.

10.1111/j.1572-0241.2002.06038.x

Pagliaro L, Rinaldi F, Craxì A, Di Piazza S, Filippazzo G, Gatto G, Genova G, Magrin S, Maringhini A, Orsini S. Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial. Dig Dis Sci 1983;28:39-43.

Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, Pudifin DJ. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986;1:523-525.

Poniachik J, Bernstein DE, Reddy KR, Jeffers LJ, Coelho-Little ME, Civantos F, Schiff ER. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc 1996;43:568-571.

Hübscher SG. Histological grading and staging in chronic hepatitis: clinical applications and problems. J Hepatol 1998;29:1015-1022.

10.1111/j.1572-0241.2004.30110.x

Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006;12:3682-3694.

10.1055/s-2004-823103

10.1016/j.hep.2003.09.022

10.1016/j.hep.2003.10.010

10.1002/hep.22742

10.1002/hep.20535

10.1111/j.1572-0241.2001.05273.x

10.1043/0003-9985(2001)125<0736:TVOSOI>2.0.CO;2

10.1016/j.jhep.2008.07.039

10.1016/j.jhep.2008.10.014

Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995;36:437-441.

Szymczak A, Simon K, Inglot M, Gladysz A. Safety and effectiveness of blind percutaneous liver biopsy: analysis of 1412 procedures. Hepat Mon 2012;12:32-37.

10.1007/s00330-004-2407-0

Bonny C, Rayssiguier R, Ughetto S, Aublet-Cuvelier B, Baranger J, Blanchet G, Delteil J, Hautefeuille P, Lapalus F, Montanier P. [Medical practices and expectations of general practitioners in relation to hepatitis C virus infection in the Auvergne region]. Gastroenterol Clin Biol 2003;27:1021-1025.

Muir AJ, Trotter JF. A survey of current liver biopsy practice patterns. J Clin Gastroenterol 2002;35:86-88.

Sebastiani G, Ghali P, Wong P, Klein MB, Deschenes M, Myers RP. Physicians’ practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey. Can J Gastroenterol Hepatol 2014;28:23-30.

10.1016/j.jhep.2006.12.002

10.1016/j.jhep.2005.02.041

Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2000;133:665-675.

10.1111/j.1478-3231.2008.01691.x

Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party; McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS, Hardikar W, Hui CK, Jafri W, Jia JD, Lai MY, Wei L, Leung N, Piratvisuth T, Sarin S, Sollano J, Tateishi R. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007;22:615-633.

10.1016/j.jhep.2011.02.023

Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol 2012;26:359-375.

Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2007;13:525-531.

Guéchot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996;42:558-563.

10.1186/1476-5926-4-6

McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, Tong MJ. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 2000;15:945-951.

Walsh KM, Fletcher A, MacSween RN, Morris AJ. Basement membrane peptides as markers of liver disease in chronic hepatitis C. J Hepatol 2000;32:325-330.

Murawaki Y, Ikuta Y, Okamoto K, Koda M, Kawasaki H. Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C. J Gastroenterol 2001;36:399-406.

Misaki M, Shima T, Yano Y, Sumita Y, Kano U, Murata T, Watanabe S, Suzuki S. Basement membrane-related and type III procollagen-related antigens in serum of patients with chronic viral liver disease. Clin Chem 1990;36:522-524.

Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aubé C, Gallois Y, Rifflet H, Maïga MY, Penneau-Fontbonne D. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997;113:1609-1616.

Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 1999;44:624-630.

Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, Yamamoto N, Sugimoto K, Murata K, Nakano T. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005;11:476-481.

10.1002/hep.20935

10.1016/j.jhep.2008.07.035

10.1016/j.jhep.2006.12.013

10.1111/j.1365-2893.2006.00743.x

10.1016/j.amjmed.2006.06.044

10.1016/j.cgh.2007.11.009

10.1111/j.1572-0241.2007.01761.x

10.1373/clinchem.2005.048389

Becker L, Salameh W, Sferruzza A, Zhang K, ng Chen R, Malik R, Reitz R, Nasser I, Afdhal NH. Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol 2009;7:696-701.

Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ; European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704-1713.

10.1016/S0140-6736(00)04258-6

10.1016/j.jhep.2006.01.007

10.1111/j.1572-0241.2006.00411.x

10.1111/j.1572-0241.2007.01466.x

10.1002/hep.21037

10.1016/j.jhep.2008.08.018

Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Ceppa P, Testa R. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003;163:218-224.

10.1002/hep.20717

10.1111/j.1572-0241.1998.044_c.x

Park GJ, Lin BP, Ngu MC, Jones DB, Katelaris PH. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol 2000;15:386-390.

10.1053/jhep.2003.50346

10.1002/hep.24105

10.1053/jhep.2002.36128

10.1002/hep.21669

10.1002/hep.22085

Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-1713.

10.1053/j.gastro.2012.02.017

10.1053/j.gastro.2008.01.034

10.1002/hep.22594

10.1002/hep.22748

10.1136/gut.2005.069153

10.1002/hep.23312

10.1002/hep.24624

10.1002/hep.22007

10.1002/hep.22056

10.1111/j.1365-2893.2009.01199.x

10.1002/hep.22577

10.1002/hep.26343

10.1002/hep.26501

10.1136/gut.2006.111302

10.1002/hep.23425

10.1038/ncpgasthep1025

10.1053/j.gastro.2008.03.001

10.1002/hep.22859

10.1111/j.1365-2036.2008.03742.x

Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350.

10.1016/j.jhep.2009.11.008

10.1111/j.1365-2893.2006.00736.x

10.1111/j.1365-2036.2011.04897.x

10.1111/j.1478-3231.2009.02101.x

10.1002/hep.24654

10.1002/hep.21665

10.1111/j.1478-3231.2005.01227.x

10.1016/j.jhep.2010.04.019

10.1002/hep.21941

Giannini E, Botta F, Borro P, Risso D, Romagnoli P, Fasoli A, Mele MR, Testa E, Mansi C, Savarino V. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut 2003;52:1200-1205.

10.1002/hep.26652

10.1053/j.gastro.2012.05.035

10.1373/clinchem.2006.070961

10.1038/ajg.2009.746

10.1002/hep.22870

10.1053/j.gastro.2011.02.058

10.1016/j.jhep.2013.11.016

Chen T, Wong RE, Alshaalan R, Wong P, Deschenes M, Ghali P, Sebastiani G. Subclinical cirrhosis: defining a new clinical entity with transient elastography. Hepatology 2013;58:123A.

10.1111/j.1365-2036.2011.04765.x

Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-1313.

10.1002/hep.20073

10.3748/wjg.v17.i41.4581

10.1002/hep.22759

10.1002/hep.20772

10.1111/j.1365-2893.2007.00932.x

10.1002/hep.21520

10.1002/hep.21835

10.1002/hep.20506

10.1016/j.jhep.2006.11.010

10.1136/gut.2008.149708

10.1111/j.1365-2893.2009.01210.x

10.1016/j.jhep.2010.05.035